Category

News
We’re keen to know how Myeloma New Zealand can help you. What you’d like to hear about on the website? What support you feel would be useful? We’d love to get your feedback and ideas. Please take the time to fill in our survey here.
Continue Reading
The FDA has granted bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma, according to Celgene Corporation and bluebird bio, the companies developing the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy. In a press release, the companies reported that the investigational agent had also been awarded PRIority MEdicines...
Continue Reading
INVITATION Patient Seminar:  Improving Survival in Multiple Myeloma Dr. Henry Chan from North Shore Hospital will be speaking at our patient seminar on his recent work looking at multiple myeloma incidence and survival outcomes in New Zealand. Dr Chan has just delivered a paper on this at the Haematology Society of Australia and NZ’s annual scientific conference. Improving...
Continue Reading
Daratumumab darzalex
Patients in Scotland will now be able to access the new myeloma treatment, daratumumab (Darzalex®) on the NHS, after the Scottish Medicines Consortium (SMC) approved it for use. Read the story here.
Continue Reading
For this week’s Article of the Week, we look at an article that describes a review of patient data from the Mayo Clinic.  The study sought to identify factors that could guide re-treatment in AL amyloidosis, with the goal of preventing organ progression.  Covering a period 1996-2014, the timeframe necessarily included a range of treatment approaches. ...
Continue Reading
For this week’s Article of the Week we have chosen a review article published in the British Journal of Haematology co-authored by MSAG member Dr Andrew Zannettino. This review focuses on the genetic changes associated with the evolution of Monoclonal Gammopathy of Unknown Significance (MGUS) and the progression to Multiple Myeloma (MM). Cutting edge genomics...
Continue Reading
For this week’s Article of the Week we have chosen an article which is particularly relevant to the results of the recent VCAT study which is currently being prepared for publication. It features a study  recently published in the British Journal of Haematology comparing the use of bortezomib consolidation therapy with observation only in patients...
Continue Reading
For this week’s Article of the Week relates to a presentation made by Petere Croucher on the osteocyte-specific protein sclerostin at the most recent MSAG meeting. It is an article published this month in Blood on the use of sclerostin to increase bone mass and reduce the incidence of fractures in multiple myeloma. Inhibiting the osteocyte-specific protein sclerostin increases...
Continue Reading
García-Guerrero et al described their laboratory study where myeloma cells from 12 patients were treated with titrated doses of panobinostat (0, 10 and 25nM). In order to assess CD38 expression, the authors used flow cytometry after exposure to panobinostat. The authors then went on to assess whether an increase in CD38 expression caused by panobinostat...
Continue Reading
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma’ is a study intended to assess the safety, efficacy and pharmacokinetics of the anti-CD38 monoclonal antibody isatuximab given in 2 different regimens in combination with lenalidomide and dexamethasone. The study included 57 patients in total with a confirmed diagnosis of multiple myeloma...
Continue Reading
1 11 12 13 14

Floor 7, 90 The Terrace
Wellington Central
New Zealand